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Themammalian target of rapamycin inhibitors (mTOR-I), sirolimus and everolimus, are immunosuppressive drugs largely used in
renal transplantation.Themainmechanismof action of these drugs is the inhibition of themammalian target of rapamycin (mTOR),
a regulatory protein kinase involved in lymphocyte proliferation. Additionally, the inhibition of the crosstalk among mTORC1,
mTORC2, and PI3K confers the antineoplastic activities of these drugs. Because of their specific pharmacological characteristics
and their relative lack of nephrotoxicity, these inhibitors are valid option to calcineurine inhibitors (CNIs) for maintenance
immunosuppression in renal transplant recipients with chronic allograft nephropathy. However, as other immunosuppressive
drugs, mTOR-I may induce the development of several adverse effects that need to be early recognized and treated to avoid severe
illness in renal transplant patients. In particular, mTOR-I may induce systemic nonnephrological side effects including pulmonary
toxicity, hematological disorders, dysmetabolism, lymphedema, stomatitis, cutaneous adverse effects, and fertility/gonadic toxicity.
Although most of the adverse effects are dose related, it is extremely important for clinicians to early recognize them in order to
reduce dosage or discontinue mTOR-I treatment avoiding the onset and development of severe clinical complications.
1. Role and Biological Function of
mTOR Inhibitors (mTOR-I)
The mammalian target of rapamycin inhibitors (mTOR-I),
sirolimus and everolimus, are agents withmany immunosup-
pressive and anti-cancer properties [1].
Themainmechanismof action of these drugs is the inhbi-
tion of mammalian target of rapamycin (mTOR). mTOR is a
regulatory protein kinase involved in lymphocyte prolifera-
tion, developmental processes such as neurologic andmuscle
generation, and tumor cell growth. Sirolimus (SRL; Rapam-
une, Wyeth Pharmaceuticals, New York City, NY, USA) was
the first mTOR inhibitor (mTOR-I) approved for use in renal
transplant recipients. It binds to the imm unophilin FK bind-
ing protein-12 (FKBP-12). Everolimus (EVR), marketed as
Certican, was approved lately, and it is structurally similar to
SLR except for the addition of an extra hydroxyethyl group at
position 40 [2]. Whereas the Tacrolimus (TAC)/FKBP-
12 complex inhibits calcineurin-induced transcription of
interleukin-2 (IL-2), the SRL/FKBP-12 and EVR/FKBP-12
complexes both bind directly to mTOR, halting T-cell pro-
gression from the G1 to the S phase of cell cycle, leading
to inhibition of IL-2-induced protein synthesis and cellular
proliferation [3].
Because of their specific pharmacological characteristics,
mTOR-I are highly effective in renal transplantation, and
thanks to their relative lack of nephrotoxicity, these inhibitors
are a valid option to calcineurin inhibitors (CNIs) for main-
tenance of immune suppression in renal transplant recipi-
ents with chronic allograft nephropathy [4–6]. However, as
reported by recent studies [7, 8], it seems clear that time and
drug dosage may have a primary role in the development of
drug-related adverse effects and clinical complications.
Additionally, the inhibition of the crosstalk among
mTORC1, mTORC2, and phosphatidylinositol-3 kinase
(PI3K) confers the antineoplastic activities of these drugs
[9]. EVR received Food and Drug Administration (FDA)
approval in 2009 for renal cancer carcinoma (RCC) and
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Table 1: Most common adverse events in mTOR-I-treated renal transplant recipients.
Adverse events Rate of occurrence (%) References
Pulmonary toxicity 2–11 [20, 21, 24, 33]
Hematopoietic adverse effects
Anemia 13–58 [6, 36, 44–47, 50, 56, 57, 70, 72, 135, 147]
Leukopenia 5–39 [6, 45, 46, 56, 66, 117, 121, 147]
Thrombocytopenia 4–45 [6, 45–47, 56, 66, 70, 117, 118, 121, 122, 147]
Metabolic disorders
Hyperlipidemia 8–87 [6, 45–47, 57, 66, 70–72, 115, 117, 118, 121, 135, 147]
Posttransplantation diabetes 3–33 [56, 70, 72, 78, 80, 115, 121, 138, 147]
Hypophosphatemia 15–20 [45, 46, 57]
Lymphedema <5 [99–102]
Cardiovascular disease 1–6 [80, 100, 117, 122, 124, 128]
Hypertension 8–58 [46, 57, 70, 72, 115, 117, 121, 122, 135]
Cutaneous adverse effects
Acne, folliculitis 9–25 [6, 57, 70, 116–118, 135, 147]
Stomatitis and mucous membrane disorders 9–64 [6, 118, 138, 147]
Edema 2–70 [6, 56, 57, 70, 121, 122, 135, 147]
Nail and hair pathologies 74 [116]
Gonadal complications <5 [123–126]
Surgical wound complication 2–20 [56, 70, 72, 133–136]
Infections 2–60 [6, 72, 117, 122, 136]
Gastrointestinal complication 2–51 [6, 46, 47, 56, 57, 70, 72, 117, 118, 121, 135, 147]
successively for tuberous sclerosis and pancreatic neuro-
endocrine tumors [10, 11]. The anticancer efficacy of mTOR-I
seems to be limited to their cytostatic and no cytotoxic
activities, so the clinical effect is stabilization rather than
regression.Therefore these drugs are extremely useful for the
immunosuppressive treatment of patients developing post-
transplant neoplasias [9].
The mechanism of antitumor activity is also correlated to
the upregulation of adhesionmolecules and to a switch to less
invasive phenotype of tumoral cells. Moreover, the inhibition
of angiogenesis is due to the reduction of vascular endothelial
growth factor (VEGF) production and decreased endothelial
sensitivity to such growth factor [12–14].
Moreover, mTOR-I may reduce the incidence of several
comorbidities associated with transplantation and chronic
kidney disease including atherosclerosis [15] and complica-
tions correlated to polycystic kidney disease [16, 17].
Although the clinical utility of this drug category is clear,
as other immunosuppressive drugs, mTOR-I may induce the
development of several adverse effects (Table 1) that need to
be early recognized and treated to avoid severe illness in renal
transplant patients.
However, although the majority of the mTOR-I clinical
trials have been performed in renal transplant patients using
SRL, it seems reasonable that EVRmay induce similar adverse
effects. Sa´nchez-Fructuoso et al. have recently reported no
difference in the rate of drug discontinuation for adverse
effects between EVR- and SRL-treated patients [18]. In addi-
tion, it is conceivable that most results from initial clinical
trials using SRL can not be compared with those obtained by
more recent studies usingEVRmainly because of the different
dosages used, dissimilar trough levels reached and drug
combinations proposed. Nevertheless, randomized clinical
trials are necessary to better address this important clinical
research topic.
In this review we focus our attention only on the main
nonrenal adverse effects/toxicities occurring in renal trans-
plant patients treated with both mTOR inhibitors.
2. Pulmonary Toxicity
Pulmonary adverse effects/toxicities are highly frequent in
renal transplant recipients treated with mTOR-I. Numerous
clinical studies have reported a frequency of this complication
of 2–11%with the onset of symptoms between 1 and 51months
after the initiation of SRL or EVR therapy [19–22].
MTOR-I-associated pneumonitis has heterogeneous clin-
ical manifestations and may begin with fever, fatigue, cough-
ing and dyspnoea, and nonspecific signs and symptoms,
which do not facilitate diagnosis [23].
Several distinct types of pulmonary damage have been
recognized, including lymphocytic interstitial pneumonitis,
lymphocytic alveolitis, bronchiolitis obliterans with organiz-
ing pneumonia, focal pulmonary fibrosis, or a combination
thereof [24, 25]. Diffuse alveolar hemorrhage has been
reported following the use of both SRL and EVR [26, 27].
The etiopathogenic mechanism of mTOR-I-associated
pulmonary toxicity is still unclear, and several in vivo and
in vitro studies have tried to define the biological machinery
associated with this heterogeneous clinical condition.
A cell-mediated autoimmune responsemay have a pivotal
role when cryptic pulmonary antigens are exposed, and this
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causes lymphocytic alveolitis and interstitial pneumonitis. T-
cell-mediated, delayed-type hypersensitivity may be another
pathogenic mechanism [19]. Additionally, Ussavarungsi et al.
have recently reported that SRL may induce granuloma-
tous interstitial inflammation which suggests a role of T-
cell-mediated hypersensitivity reaction to circulating anti-
gens or immune complexes in the lungs [28]. T-cell lym-
phocytes produce IL-2 and IFN-gamma which stimulate
alveolar macrophages and also produce TNF-alpha and
IL-1. Activated macrophages secrete several chemokines
such as monocyte chemoattractant protein-1 (MCP-1) and
macrophage inflammatory protein 1 alpha (MIP-1𝛼) and
transform into epithelioid cells and multinucleated cells
contributing to cellular infiltration and granuloma forma-
tion [29]. Additionally, the existence of a dose-dependent
effect was strongly suggested because this disease has been
observed particularly in kidney transplant patients receiving
high doses of SRL.
Therefore, to assume a possible correlation between pul-
monary disease and mTOR-I administration, patients should
present the following conditions:
(1) exposure to mTOR-I preceding the onset of pul-
monary symptoms;
(2) exclusion of infection or alternative pulmonary dis-
ease, including toxicity due to other drugs, such as
azathioprine, beta-blockers, fibrates, sulfamethoxa-
zole, and trimethoprim;
(3) resolution after mTOR-I discontinuation or mini-
mization;
(4) presentation of a lymphocytic alveolar cellular profile
and pathological findings, although nonspecific, con-
sistent with drug-induced pulmonary toxicity.
Then, to achieve a correct diagnosis, radiographic tests,
computer tomography (CT) and bronchoalveolar lavage
(BAL), even whether often unspecific, are extremely useful.
CT images generally describe ground glass opacities and/or
peripheral interstitial infiltrates, while BAL generally shows
an increased number of CD4+ cells with mast cells and
eosinophils [19]. It is unquestionable that, whenpossible, BAL
should be performed to rule out infectious processes in these
immunocompromised patients. Then, pulmonary function
tests, demonstrating a reduction of the diffusing capacity of
carbon monoxide, are less helpful, with this condition being
in overlap with several other clinical features [30, 31].
In most cases, it is also necessary to early perform a lung
biopsy. Usually, the lung biopsy pattern may include several
histological features such as the intra-alveolar nonnecrotizing
epitheloid granuloma, lymphocytic interstitial inflammation,
and a focal pattern of organizing pneumonia [32].
The treatment of these pulmonary forms is variable, and
it needs a multidisciplinary approach (e.g., pneumologists,
infectiologists, and nephrologists) and a combined use of sev-
eral drugs (e.g., antibiotics, corticosteroids, and immunosup-
pressive drugs). Nevertheless, as reported byWeiner et al., the
treatment of choice of these complications results generally
in drug withdrawal [33, 34]. However, in some cases, mTOR-
I dose reduction could be sufficient to control symptoms
and avoid disease progression/complication. As described by
White et al. the same strategies have been adopted in patients
affected by advanced renal cell carcinoma chronically treated
with EVR [30]. Additionally, a published overview of cases of
mTOR inhibitor-related noninfectious pneumonitis in liver
transplant recipients (104 treated with SRL and 9 with EVR)
confirms this therapeutic strategy. In fact it was reported that,
after diagnosis of mTOR-I pulmonary adverse effects, SRL
was withdrawn in 87/104 patients, with complete resolution
in 82 patients, partial resolution in 1 patient, and 4 deaths.
Of the 13/104 patients who continued SRL at a reduced dose,
8 showed complete resolution and the remaining 5 either
had persistent symptoms or relapsed. All five patients had
complete resolution on drug discontinuation. Among the
nine patients treated by EVR, drug was withdrawn in eight
patients and continued at a reduced dose in one patient. All
experienced complete recovery [35].
Concerning corticosteroids, it remains unclear whether
these drugs may be useful to treat mTOR-I-related pul-
monary complications [31]. No studies have adequately ana-
lyzed the effect of additional/different therapies for the trea-
tment of pulmonary adverse effects/toxicities occurring in
renal transplant recipients.
Therefore, in conclusion, all clinicians in charge of trans-
planted patients should be aware of this new entity of mTOR-
I-associated pneumonitis as an alternative to the diagnosis of
an opportunistic infection. Indeed, discontinuation or dose
reduction of mTOR-I led in most of the cases to the complete
and lasting resolution of symptoms.
3. Hematopoietic Adverse Effects
Hematopoietic adverse effects and bone marrow toxicity
often occur after renal transplantation in patients undergoing
mTOR inhibition. In particular, mTOR-I-treated patients
develop anemia, leukopenia, and thrombocytopenia [36, 37].
3.1. Anemia. Anemia is common after kidney transplan-
tation and has been recognized as a late complication of
transplantation [38, 39]. It has been linked to multiple
factors including poor allograft function, acute and chronic
rejection, iron deficiency, viral infections, hemolytic uremic
syndrome, treatment with angiotensin converting-enzyme
inhibitors (ACEIs) or angiotensin receptor blockers (ARBs)
and immunosuppressive drugs [40–43].
Initial phases 1 and 2 dose escalation studies found a
slower recovery of postoperative hemoglobin (Hb) levels
in SRL-Cyclosporin A (CsA)/prednisone-treated compared
withCsA/prednisone-treated renal transplant recipients [44].
Groth et al. reported an approximately 35% incidence of early
posttransplant anemia in SRL-treated patients versus 25%
in a CsA-treated group [45]. Kreis et al. observed a 43%
incidence of anemia with SRL compared with 32% in the CsA
arm in studies in which both treatment arms received either
azathioprine or mycophenolate mofetil (MMF) [46].
A dose relationship between SRL and anemia develop-
ment was documented in phase 3 trials comparing SRL
2mg/day with SRL 5mg/day administered along with CsA
and corticosteroids (24 versus 35%, resp.) [46]. A second
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phase 3 trial comparing SRL/CsA/corticosteroids with pla-
cebo/CsA/corticosteroids found a 36% incidence of anemia
(SRL 2 mg/day) versus 56% (SRL 5mg/day) versus 16%
(placebo) [47].
In a study comparing SRL/MMF/prednisone with tacro-
limus/MMF/prednisone, mean Hb was again significantly
lower in SRL-treated patients at 1 month [48]. Friend et al.
found that long-term use of SRL/prednisone resulted in a
lower prevalence of anemia compared with SRL/CsA/predni-
sone, despite higher SRL concentrations [49].
Augustine et al. comparing CNI/SRL with CNI/MMF
therapy in kidney and kidney-pancreas transplant recipients,
found a higher prevalence of anemia in the SRL versus MMF
group at 6 months (57 versus 41%, resp.) and 12 months
(57 versus 31%, resp.) [36]. These results were confirmed by
another study [50].
Multiple conversion studies, then, have shown that swi-
tching from CNI to SRL in long-term renal transplant
patients results in a significant increased degree of anemia,
suggesting but not proving a direct causative role. Thaunat
et al. reported a decrease of Hb (mean decrease of 2.5 g
per 100mL) in 86.9% of patients switched from CNI-based
immunosuppression to SRL-based immunosuppression for
chronic allograft nephropathy/chronic CNI nephrotoxicity
[51]. Similar results were obtained byMaiorano et al. [52] and
Diekmann et al. [53].TheCONVERT trial found that anemia
was reported in 37.4% of patients converted to SRL versus
18.7% of patients continued on CNI [54].
Also EVRhas been associatedwith anemia [55, 56]. In the
B251 study were reported significantly more anemia-related
adverse events at 36months for EVR 1.5mg/day and 3mg/day
compared with MMF (32.1% and 39.2% versus 21.4%, resp.)
[57].
Various mechanisms have been proposed for mTOR-
I-induced anemia, but the complete molecular/biological
machinery involved is not fully understood. In patients
treated with both SRL and EVR, anemia seems mainly to
be due to the antiproliferative effect of the drug on bone
marrow progenitor cells and a possible direct impact on
iron homeostasis [58]. However, as reported by Thaunat
et al. in 2005, there is a close relationship between chronic
inflammatory status and mTOR-I-related anemia [51]. Addi-
tionally, the same group has recently suggested that SRL
might trigger a destabilization of the inflammatory cytokine
balance in transplanted patients that promotes a paradoxical
inflammatory response with mild stochastic clinical symp-
toms in the week following drug introduction, explaining
partially SRL-associated anemia with low serum iron levels
and microinflammation [59]. Similarly, Sa´nchez Fructuoso
et al.[55] reported that after conversion from CNI to EVR
there is a significant development of anemia associated with
low serum iron levels and microinflammation.
Therefore, based on the multifactorial reasons of the
mTOR-I-related anemia, it is now clear that physicians should
adopt a rigorous approach to evaluate and treat the anemia in
these patients. Transfusion is uncommonly required in pre-,
peri-, and posttransplant courses; if performed, leukocyte
filtration should be used to decrease the risk of allosensiti-
zation and transmission of viral infection (including CMV).
The success of EPO-stimulating agents (ESAs) in increasing
hemoglobin levels may be related to the cause of anemia
and clinical reasons for anemia correction [38, 39]. The
data suggest that ESA treatment soon after transplantation
shortens the time of hemoglobin correction [60, 61]. Then,
iron repletion is important, as even patients with suboptimal
erythropoietin levels can correct anemia with adequate iron.
Iron deficiency is common in the peritransplant period and
treatment decreases the incidence of anemia at six months
[62, 63].
3.2. Leukopenia and Thrombocytopenia. Since the early clin-
ical trials with SRL in transplantation in 1996, it emerged
that leukopenia and thrombocytopenia were amongst the
most common adverse effects of the mTOR-I. These adverse
effects were the most likely reasons for the intervention
with mTOR-I to be terminated [44, 45, 64]. During the first
2 months of treatment, dose-dependent thrombocytopenia
and leukopenia may occur in approximately 20% of renal
transplant recipients [65].
Groth et al. reported in a randomized multicentre study
[45] including first cadaveric renal allograft recipients ran-
domized to CsA (𝑛 = 42) or SRL (𝑛 = 41) in association
with corticosteroids and azathioprine that thrombocytopenia
and leucopenia were striking adverse effects of SRL.However,
these abnormalities improved 2 months after transplantation
when the SRL target trough level was lowered from 30 to
15 ng/mL.
In another study from 14 European centres including 78
first cadaveric renal allograft recipients randomized to receive
SRL (𝑛 = 40) or CsA (𝑛 = 38), a significant higher rate
of thrombocytopenia has been reported in the SRL-treated
group of patients compared to CNI-treated control (45%
versus 8%) [46]. All patients received corticosteroids and
MMF2 g/day. SRL doses were adjusted to achieve steady-state
trough levels of approximately 30 ng/mL for 2 months and
15 ng/mL thereafter.
Also EVR has been associated with both leucopenia and
thrombocytopenia. As reported by Kovarik et al. leukocy-
topenia occurred in 11–19% of patients, while the incidence of
thrombocytopenia was 10–17% of patients chronically treated
with EVR [66].
One hypothesis to explain the myelosuppressive effects
is based on in vitro findings that mTOR-I potentiate plate-
lets destruction via agonist-induced aggregation. mTOR-
I-treated platelets display increased sensitivity to adeno-
sine diphosphate and/or thrombin receptor agonist peptide,
resulting in augmented platelet aggregation and granule
secretion [67]. An alternate hypothesis is that the myelo-
suppressive property of SRL is due to the inhibition of the
signal transduction via the gp130 [beta] chain shared by a
variety of cytokine receptors, including interleukin-11 [68],
granulocyte colony stimulation factor, and erythropoietin,
which stimulate the production of platelets, leukocytes, and
erythrocytes, respectively [69].
Drug-induced thrombocytopenia and/or leukopenia are
generally self-limited toxicities. Only 7% of patients require
SRL dose reduction and 4% temporary drug withdrawal. No
patient requires permanent discontinuation of SRL therapy.
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When dose reduction is necessary, amelioration of the toxic
effects are evident within 24 hr, although up to 50 days are
required for full recovery in a few patients [65].
4. Metabolic Disorders
The most common metabolic disorders following mTOR-I
treatment are associated with a severe deregulation of the
lipid and glucidic metabolism. Prevention, early recognition,
and treatment of these complications may have a significant
impact on long-term survival of these patients.
4.1. Hyperlipidemia. Dyslipidemia is a major risk factor for
posttransplant cardiovascular-related morbidity and mortal-
ity [69].
Several papers have reported that mTOR-I are well-
recognized major causes of posttransplantation hyperlipi-
demia. They increase high-density lipoproteins (HDL), low-
density lipoproteins (LDL), cholesterol, and triglycerides in
approximately 40 to 75% of patients who receive this therapy
[4, 70–72]. In the same way the upregulation of adipocyte
fatty acid-binding protein (aP2) expressed in macrophages
andmonocytes plays a key role in the increased accumulation
of triglycerides [73].
The mTOR-I-induced dyslipidemia constitutes a critical
clinical problem because the annual risk of a cardiovascular
event is almost 50-fold greater for a renal transplant patient
than for the general population, and these events account for
over one-third of all deaths [74].
A study of Morrisett et al. observed that cholesterol
and triglyceride levels increase after 2–4 weeks of initiation
of therapy, and this alteration reverted to near-baseline
levels within 8 weeks after discontinuation of treatment.
This demonstrated that hyperlipidemia is reversible and dose
dependent [75].
The 3-Hydroxy-3-methyl coenzyme A (HMG-CoA)
inhibitors (statins) alone or in combination with a second-
line agent remain the main therapeutic option for mTOR-I-
induced hyperlipidemia [76].
4.2. Posttransplantation Diabetes. Posttransplantation dia-
betes is a relatively frequent and unfortunate complication
in patients carrying renal allografts [77]. All available infor-
mation regarding potentially modifiable factors associated
with or leading to diabetes should be part of a thoughtful
decision-making process regarding the optimal maintenance
of immunosuppression.
To date, only a few clinical studies have suggested that SRL
and its analogues are associated with hyperglycemia [78–81].
Themechanisms by which SRLmay cause new-onset dia-
betes (NOD) are not clearly defined. SRL acts on the mTOR,
a serine/threonine kinase that integrates signals from various
nutrients and growth factors to regulate protein translation
through a variety of downstream effectors. Physiologic con-
ditions such as hyperinsulinemia promote serine/threonine
phosphorylation of insulin receptor substrate proteins that
inhibits their function and promotes their degradation. Over-
activation of mTOR/S6K cascade would exert a significant
negative effect on the activity of downstream components of
the insulin/PI3-K pathway, such as AKT, leading to insulin
resistance [82, 83]. Inhibitors of mTOR would therefore
be expected to prevent development of insulin resistance
through this mechanism.
Additionally, Di Paolo et al. [82] studied 30 patients
treated with long-term SRL and reported an unexpected
impairment of insulin receptor substrate signaling and AKT
activation, a finding that could help to explain deterioration
of glucose metabolism in SRL-treated patients.
Other mechanisms that have been proposed for the
induction of hyperglycemia by SRL include ectopic triglyc-
eride deposition leading to insulin resistance [84, 85], impair-
ment of insulin-mediated suppression of hepatic glucose
production, or a direct toxic effect on pancreatic 𝛽 cells
[86, 87].
Another interesting hypothesis is that mTOR is involved
in insulin signaling, and its inhibition may impede insulin-
related gene transcription and expression, including glu-
cose transporters. In particular, SRL abrogated the insulin-
mediated increase in GLUT1 protein synthesis through
partial inhibition of GLUT1 mRNA translation and partial
inhibition of the rise inGLUT1mRNA, resulting in the failure
of insulin to stimulate glucose uptake. Similarly, mTOR is an
inducer of ribosomal S6 kinase (S6K), and SRL blocks S6K
activation or induces S6K inactivation through inhibition
of T389 phosphorylation interfering with the transcript of
insulin. This action may impact blood sugar levels [88].
Currently, it is considered that patients with an A1C
assay ≥6.5% should start on glucose-lowering agents. As for
type 2 diabetes, a stepwise approach should be adopted. The
first step includes hygiene-dietetic recommendations (weight
control, diet, and exercise).The second step is the initiation of
an oral agent in monotherapy. The choice of the drug should
take into account the patient-specific factors, graft function
(some drugs or active metabolites are eliminated by the
kidney), specific side effects, and potential pharmacokinetic
interactions with immunosuppressive drugs (mainly inter-
action with CNI or mTOR-I through metabolism mediated
by cytochrome P450, family 3, subfamily A, polypeptide 4/5
[CYP3A4/5]). The third step is a combination of oral agents
with different mechanisms of actions. Combination therapy
has not been investigated in kidney allograft recipients. The
last step is the initiation of insulin with or without oral agents.
If the target for glucose control is not achieved within 2–
4 months, lifestyle interventions should be reassessed and
patients should move to the next step [77].
About the immunosuppressive management of patients
undergoing mTOR-I-related posttransplantation diabetes,
there are still not well-defined guidelines, and although
the switch to cyclosporine might be considered in selected
patients, at the state of the art, no randomized clinical trial
has been performed to better address this important point.
Teutonico et al. then reported that the discontinuation of
CNIs and their replacement by SRL fails to ameliorate the
glycometabolic profile of kidney transplant recipients. Rather,
it is associated with a worsening of insulin resistance and an
inappropriately low insulin response [79].
Unfortunately, experimental and clinical data on EVR are
more scant.
6 Clinical and Developmental Immunology
4.3. Metabolic Syndrome. The concept of metabolic syn-
drome was first described by Reaven [89] as a combination of
central obesity, dyslipidemia, hypertension, and fasting hype-
rglycemia, all thought to be based on insulin resistance
and inflammation as the common pathophysiologic distur-
bances. In the general population, the presence of metabolic
syndrome is associated with a risk for overt diabetes and
cardiovascular diseases [90–92]. In addition, metabolic syn-
drome has been associated with proteinuria and reduced
GFR, suggesting a link to chronic kidney disease [93, 94].
To the extent that diabetes (i.e., new-onset diabetes after
transplantation), cardiovascular disease, and proteinuria are
common complications of kidney transplantation, the role of
metabolic syndrome in kidney transplantation recently has
attracted a great deal of interest. Finally, the pathophysiology
of the syndrome observed in the general population is
dramatically altered by the effects of immunosuppressive
medications in kidney transplant recipients. MTOR-I may
have a primary effect [95].
5. Hypophosphatemia
A reduction in phosphate levels is an important toxicity of
mTOR-I, therapy but the exact mechanism of this effect is not
known. Symptoms of hypophosphatemia, including fatigue
and weakness, occur when plasma phosphate concentration
is <2mg/dL [96], but when the levels drop to <1mg/dL,
serious complications can take place including confu-
sion, weakness, myocardial dysfunction, and rhabdomyolysis
[97].
Oral supplementation or the increment of phosphate
intake from diet may be adequate for most patients.
6. Lymphedema
A study of Langer and Kahanshows that up to 38% of patients
treated with cyclosporine and prednisone in association
with SRL may present lymphoceles [98]. Lymphedema is a
relatively rare adverse effect of mTOR-I therapy [99–102],
but the underlying biological/physiological mechanism is not
completely clarified.
Aboujaoude et al. have hypothesized that the lymphe-
dema could be strongly associated with the enhanced lymph
flow and the lymphatic disruption secondary to the surgical
procedures, together with the well-known increased vascular
permeability and vasodilation caused by SRL [103].
Moreover Huber et al. showed an antilymphangiogenic
activity of mTOR-I which is the common denominator
in the pathophysiology of edematous states. In particu-
lar they reported that rapamycin administration impairs
downstream signaling of VEGF-A through inhibition of
the mTOR/p70S6K pathway in lymphatic endothelial cells
(LECs) and also interferes with the intracellular pathway
activation of LEC by VEGF-C, themain initiator of lymphan-
giogenesis. Interestingly this antilymphangiogenic activity is
not restricted to a specific mTOR-I; rather it is a general
phenomenon of mTOR inhibition [104].
Before establishing the diagnosis of lymphatic disease
caused by mTOR-I, it is necessary to rule out other potential
causes such as neoplasia, infection, venous obstruction, and
genetic predisposition. A chest radiography, CT, or ultra-
sound study and laboratory tests can help in the differential
diagnosis.
Reduction or discontinuation of the immunosuppressive
drug therapy is, at the state of the art, the only worthy strategy
in patients with lymphedema.
7. Cardiovascular Disease
The renal transplant population is highly vulnerable to
premature CVD, the major cause of death with a functioning
graft [105]. The risk of occurrence of a cardiovascular event
in renal transplant patients treated with mTOR-I could be
related to hypercholesterolemia, hypertriglyceridemia, and
new-onset diabetes. However, to the best of our knowledge, at
the state of the art, no reports (including the most important
clinical trials) have strongly demonstrated that the presence
of CV risk factors actually translates into an increased
incidence of CV events or CV diseases.
However, some in vitro experiments have also reported a
prooxidant induced by mTOR-I whose effects may decrease
NO availability [106–111].
This result is in line with some recent evidence reported
by international cardiovascular research groups suggesting
that SRL causes marked vascular dysfunction and nitrate
resistance after continuous treatment for 7 days in animal
model.This impaired vasorelaxationmay, in part, be induced
by upregulated mitochondrial superoxide release as well as
by an upregulation of NADPH oxidase-driven superoxide
production. Both processes could contribute to endothelial
dysfunction observed after coronary vascular interventions
with sirolimus-coated stents [111].
Another debated adverse effect related to mTOR-I is
hypertension. As underlined by Reis et al. mTOR-I, similarly
to CNI, have hypertensive effects. However, while CNI sig-
nificantly promotes tachycardia and oxidative stress, mTOR-
I seem to mainly interfere with lipid profile, hemorheology,
and serotonin (5-HT) levels, without the same influence on
catecholamine contents and lipid peroxidation. Thus, the
cardiovascular disturbances underlying arterial hypertension
development might be associated with distinct molecu-
lar/cellular signatures hypothetically explained by differences
in the mechanism of action of immunosuppressants [112].
On the contrary, Joannide`s et al. [113] have recently
demonstrated that a CsA-free regimen based on SRL reduces
aortic stiffness, plasma endothelin-1, and oxidative stress in
renal recipients suggesting a protective effect on the arterial
wall thatmay be translated into cardiovascular risk reduction.
This study was in line with others demonstrating a lower
hypertension development in mTOR-I-treated compared to
CNI inhibitors-treated patients [114, 115].
However, based on contradictory research reports, it
is unquestionable that these data are insufficient to define
the mTOR-I systemic cardiovascular influence and to draw
definitive clinical conclusions. Therefore, additional studies
are necessary to evaluate short- and long-term CV effects of
mTOR-I treatment in renal transplant patients.
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8. Cutaneous Adverse Effects
The clinical side effects of mTOR-I in the field of derma-
tology are edema, acne, epistaxis, aphthous ulceration, and
vasculitis. Mahe´ et al. have performed a cross-sectional study
in renal transplant recipients receiving SRLwhich underwent
a dermatological examination. The main cutaneous adverse
events they observed were infection, edema, mucous mem-
brane pathologies, and nail disorders [116].
8.1. Acne. Acne is reported in 15% to 25% of organ transplant
recipients treated with SRL [117, 118]. Mahe´ et al. have
reported skin eruptions resembling acne, mainly located on
the face and trunk, in 46% of evaluated patients. Moreover
the male predominance of these acne-like eruptions suggests
that this side effect is hormone dependent [116].
8.2. Mucous Membrane Disorders. One of the most common
side effects reported in clinical trials of mTOR-I has been
mucositis, probably because of the direct toxic effect of these
drugs on oral and nasal mucous membranes. Numerous
clinical trials have reported aphthous ulcerations or oral
ulcerations [47, 119]. Frequently they are confined to the soft
mucosa of the mouth and very common on the tongue and
lips. Mouth ulcers usually occur just after the introduction of
SRL treatment but most of the time are transient. However if
persistent, these painful and debilitating lesions lead to either
dose reduction or discontinuation of mTOR-I in a significant
number of patients [120].
Topical steroid, iodine, or topical analgesic may be used
to reduce pain and to promote disappearance of the ulcer. If
symptoms persist, mTOR-I should be discontinued and pos-
sibly restarted at a lower dose after resolution of symptoms.
Anyway it is important to educate patients to maintain good
oral hygiene and informpatients about this side effect. Finally,
it is important to perform a careful oral examination during
the routine followup.
8.3. Edema. Chronic edema has been reported in 8% to 62%
of renal transplant recipients receiving SRL treatment [103,
121, 122].
Mahe´ et al. have found chronic edemas (lastingmore than
1 month, resistant to diuretics and without local, renal, or
cardiac causes) in 55% of evaluated renal transplant recipi-
ents. Edemas affected primary lower limbs and are soft and
noninflammatory.Angioedema (acute subcutaneous edema),
found in 15% of patients, developed within a few hours
and disappeared in less than 4 days. They were nonpruritic,
nonerythematous, and localizedmainly on the face, with oral
cavity involvement [116].
8.4. Nail and Hair Pathologies. Nail abnormalities associated
with SRL treatment include fragile and thin nails, longitudi-
nal ridging, distal onycholysis, and erythema.
Skin and scalp hair abnormalities comprised mild alope-
cia or hypertrichosis of the face [116]. In most cases these
adverse events were not serious, but in 12% of patients it has
been necessary to withdraw the therapy.
9. Gonadal Impact
In the last years several studies have emphasized the impact
of SRL on male gonadal function. In detail these studies have
focused on sex hormones production, erectile function, and
fertility. Regarding the balance on sex hormones production,
three studies have revealed significantly lower testosterone
levels and a significant increase in gonadotrophic hormones
(FSH and LH) in patients treated with SRL [123, 124]. As
regard the impact of SRL on sperm, a significant reduction
in total sperm count and fathered pregnancy rate in patients
who receive SRL compared to patients with SRL-free regimen
has been shown [125, 126]. The molecular mechanisms by
which mTOR-I induces a decrease in testosterone level and
sperm impairment still remain partly unknown. In an animal
model Feng et al. found that SRL plays a central inhibitory
role on a stem cell factor (SCF)/c-kit-dependant process
in spermatogonial proliferation via the PI3-K/AKT/p70S6K
pathway [127].
10. Bone Diseases
Posttransplant renal osteopathy is a clinical posttransplant
complication associated with morbidity and mortality due
to the increased frequency of bone fractures compared
with general population [128]. Osteopenia, osteoporosis, and
osteonecrosis represent the most common complications
related to renal transplant [129]. In a cross-sectional study,
osteoporosis was observed in 40% and bone fracture in
44% of renal transplant recipients evaluated 8 years after
transplantation [130]. Certainly, steroid treatment repre-
sents the more important pathogenic factor of osteopenic-
osteoporosis syndrome in these patients. In experimental
study on rats, SRL increased remodeling and growth retar-
dation of bone but did not produce bone loss [131].
Contrarily, EVR directly inhibits bone resorption con-
trolled by osteoclasts, and then it should be used in patients
with concomitants bone disease [132].
11. Surgical Wound Complication
SRL treatment has been reported to be associated with a
greater incidence of wound-healing problems than other
maintenance immunosuppressive agents [133–136]. This
effect is likely related to its ability to impair signal transduc-
tion of fibroblast and endothelial growth factors [137].
Knight et al. have evaluated the risk factors for wound
complications (infection, lymphocele, and/or incisional her-
nia) in renal transplant recipients with de novo SRL treat-
ment. They found that one-third of recipients suffered at
least one wound complication after one-year followup. The
independent risk factors for the development of these com-
plications are age, obesity, Caucasian race, and high dose of
SRL in the first fewdays after transplantation.They concluded
with useful recommendations including the avoidance of a
large loading dose of SRL and delay the introduction of this
agent for several days particularly for Caucasian, older aged
recipients, and patients with a BMI > 30 [138].
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12. Infections
The severe infections are frequent cause of mTOR-I discon-
tinuation [18, 139, 140] and one of the leading causes of death
in renal transplant recipients [141, 142]. In particular, several
biomolecular studies have shown that SRL is able to inhibit
interleukin-12-induced proliferation of activated T lympho-
cytes [143] and IFN-𝛾 production of the lymphocytes. Both
cytokines are known to be critical in protective immunity to
intracellular bacteria (e.g., mycobacterium) [144].
Literature evidence, then, suggests that both SRL- and
EVR-based regimens are associated with low CMV infection
rate in comparison with other immunosuppressive regimens
[141, 145].Themechanism underlying the apparent beneficial
effect of SRL in reducing the risk of CMV-related infection
and invasive disease in this patients’ population remains
speculative butmay relate to the effect ofmTOR inhibition on
CMVreplication.As an obligate intracellular organism,CMV
must utilize the intrinsic metabolic pathways of the host cell
to direct the synthesis of proteins that are essential to its
replication. Since mTOR serves as a key regulator of cellular
protein synthesis, its inhibition by SRL may, in turn, inhibit
CMV replication. Experimental models of CMV infection
suggest that SRL impairs, but does not entirely prevent, CMV
replication, so other mechanisms are likely involved as well
[146].
However, further investigations should be undertaken to
better analyze the biological/biomolecular machinery associ-
ated with this condition, and randomized clinical trials with
homogeneous antiviral prophylaxis, standardized definitions,
and adequate statistical power need to be performed to
confirm these clinical observations.
13. Others
Other complications, reported in approximately 15–20%,
include gastrointestinal side effects (e.g., diarrhea, vomiting,
and anorexia) [147]. Gastrointestinal leukocytoclastic vas-
culitis is a rare adverse effect reported in a few cases of use
of SRL. It is characterized by diffuse mucosal thickening of
the antrum, duodenum, and jejunum. Esophagogastroduo-
denoscopy revealed erythema, swelling, and white plaques in
the antrum, asymmetrical pylorus, and granular swelling of
the third portion of the duodenum [148]. In presence of these
complications, drug discontinuation is encouraged.
Fatigue, alterations in taste, and asthenia are other com-
mon toxicities. These symptoms were usually manageable
with a reduction in the drug dose [149].
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